A randomized, single-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on best available therapy.
This study is testing a new medication called apraglutide for adult patients who have a severe gut problem known as acute graft versus host disease (aGVHD). This condition can happen after a stem cell transplant where the new immune cells attack the patient's body. The study focuses on people whose aGVHD in the gut hasn't improved with steroid treatments. We want to find out if apraglutide is safe to use and how well it works to reduce the symptoms of aGVHD in the gut. Researchers will be carefully monitoring for any side effects and checking if patients' gut health improves over time. This is a Phase II study, meaning we're exploring how effective the treatment is.
At a glance
What is this study about?
This study, called a clinical trial, is looking into a new treatment called apraglutide for a condition called acute graft versus host disease, often shortened to aGVHD. This serious condition can happen after a patient receives a stem cell transplant, where the new immune system cells from the donor start to attack the patient's own body, particularly in the gut, skin, or liver. In this specific study, we're focusing on patients with aGVHD that affects the gut, and importantly, hasn't improved with standard steroid treatments.
The main goal of this research is to understand if apraglutide is safe and if it helps improve aGVHD in the gut. Researchers will be carefully watching for any side effects the drug might cause. They will also measure how well patients respond to the treatment, looking at whether their gut symptoms get better and if their overall condition improves over several weeks and months. This is a 'Phase II' study, which means we are exploring how effective the drug might be and continuing to gather important safety information.
By taking part, patients could help medical experts learn more about treating this challenging condition. Finding new and better ways to manage severe aGVHD that resists usual treatments is very important for improving the lives of people affected by it.
Key takeaways
- This study tests a new drug (apraglutide) for gut aGVHD.
- It's for adults whose aGVHD hasn't improved with steroids.
- The main goals are to check the drug's safety and effectiveness.
- You would receive the drug and have careful medical check-ups.
- Taking part helps advance understanding of aGVHD treatment.
Who may be eligible?
This study is for adults aged 18 and over. Both men and women can take part.
You would be considered for this study if you have acute graft versus host disease (aGVHD) that affects your gut. Importantly, your aGVHD must be serious (specifically, Grade II to IV as doctors describe it) and it must not have gotten better with the usual steroid treatments.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of acute graft versus host disease (aGVHD) in your gut?
- Has your gut aGVHD not gotten better with standard steroid treatments?
- Are you generally able to attend regular clinic visits for monitoring?
What does participation involve?
If you decide to take part in this study, you would receive the new drug, apraglutide. You would have regular visits to the clinic where doctors and nurses would monitor your health very closely. These visits would involve check-ups, blood tests, urine tests, and sometimes heart checks (ECGs).
Researchers will be looking out for any side effects you might experience and tracking how your gut aGVHD symptoms change over time. They will also check if your body creates any particular reactions to the drug. The study will involve follow-up appointments over several months to see how you are doing in the long term. This careful monitoring ensures we gather all the necessary information about the drug's safety and how well it works.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is aGVHD?
aGVHD (acute graft versus host disease) is a serious condition that can happen after a stem cell transplant when the new donor cells attack the patient's body, often affecting the gut, skin, or liver.
What is apraglutide?
Apraglutide is a new investigational drug being tested to see if it can help treat aGVHD, especially when other treatments haven't worked well.
Why is this study only for people whose aGVHD hasn't responded to steroids?
This study is looking for new options for patients with severe aGVHD that hasn't improved with standard steroid treatments, as these cases are often harder to manage.
Will I know if I'm getting apraglutide or a different treatment?
This is a 'single-blind' study, meaning you won't know if you're getting apraglutide or another ongoing treatment, but your doctors will. This helps make the study results more reliable.
How long would I be in the study?
The study involves initial treatment and then follow-up appointments over several months to continuously monitor your health and the drug's effects.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.